Please ensure Javascript is enabled for purposes of website accessibility

How Does the AstraZeneca Vaccine Measure Up to Rivals?

By Adria Cimino - Updated Apr 1, 2021 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They all have one thing in common: Efficacy beats the bar set by the FDA.

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss whether lesser efficacy versus rivals will hurt the AstraZeneca (AZN 2.46%) coronavirus vaccine candidate.

Corinne Cardina: How did these numbers stack up to the vaccines we're already familiar with? Obviously, Johnson & Johnson is one-dose, it's a little bit of apples to oranges there. The Pfizer and the Moderna vaccine uses a completely different technology because they're mRNA. But in terms of efficacy, is this on par with what we're seeing?

Adria Cimino: It's less than Moderna and Pfizer, they're up at 94, 95%. They're really, really high. However, again we have to put it into perspective. Their trial took place a little bit earlier. When they generated their data, it was before all these strains were gaining ground. Any of the recent data that comes out just in recent weeks had a lot of the strains involved too. It's very difficult to compare them exactly. The best thing to say is that they all are pretty strong vaccines, they're all pretty good. The idea of having 60-plus% efficacy is already very strong. The FDA, it originally set a bar for 50% and higher. We're looking at some pretty good vaccines here.

Cardina: Certainly. Ultimately, the 100% efficacy in severe disease prevention is very, very important and something to keep in mind.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$64.69 (2.46%) $1.55
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.68 (1.03%) $1.83
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.85 (1.86%) $0.93
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.88 (-0.75%) $-1.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.